

(Patient Label)



POSTNATAL CLINICAL CYTOGENETICS

REQUISITION FORM

Procedure: CYTO 012

Please provide all pertinent information

Procedure: CYTO 012
Effective: 3/1/2022

PATIENT INFORMATION		SPECIMEN INFORMATION	
ID#		Collection date:	Time:
Name: Last First MI		Collected by:	M.D.
Date of birth:	Sex: M F	SPECIMEN TYPE: SEE BOTTOM OF FORM FOR SPECIFICATIONS ☐ Blood ☐ Bone marrow ☐ Bone core biopsy ☐ Lymph node ☐ Stem cell ☐ Solid tumor ☐ Paraffin embedded tissue ☐ Other: _____	
Location / Clinic: _____			
REPORTING INFORMATION: Attending Physician: _____ UPIN#: _____ Phone/Pager: _____ Ordering Pathologist/Physician: _____ UPIN#: _____ Phone/Pager: _____ Send copy to: _____ Address: _____ Fax: _____ NOTICE TO ATTENDING PHYSICIANS: Medical necessity for the test(s) requested must be indicated by ICD-10 codes. ICD-10: _____			
CONSTITUTIONAL CYTOGENETIC TESTS REQUESTED: ☐ KARYOTYPE AND FISH ☐ KARYOTYPE ONLY ☐ FISH ONLY			
Constitutional Clinical Indications ☐ Dysmorphic features ☐ Trisomy 13,18, 21 ☐ Multiple congenital anomalies ☐ Sex chromosome abnormalities ☐ Developmental Delay / ID / Autism ☐ Prenatal Confirmation ☐ Ambiguous genitalia ☐ Multiple miscarriages ☐ Other: _____ G ____ A ____ P ____		Constitutional FISH ☐ Aneuploidy (X,Y,13,18,21) ☐ Turner Syndrome (45,X) ☐ SRY Yp11.31 ☐ DiGeorge / VCF 22q11.2 ☐ Steroid Sulfatase Xp22.3 ☐ Other: _____	
		MICROARRAY FOLLOW-UP: Proband MRN _____ ☐ Confirmation abnormal microarray. ☐ Parental follow-up abnormal microarray proband sample is also required	
ONCOLOGY CYTOGENETIC TESTS REQUESTED: ☐ KARYOTYPE AND FISH ☐ KARYOTYPE ONLY ☐ FISH ONLY ☐ Interpretation/consultation not requested [Chromosome / FISH analyses include pathologist interpretation and consultation unless indicated.]			
☐ NEW LEUKEMIA ☐ AML ☐ MDS ☐ MPN ☐ CML ☐ ALL ☐ CLL ☐ LYMPHOMA ☐ OTHER: _____ (Indicate site of solid tumor)			
Bone Marrow Sex-Mismatch Transplant FISH: ☐ X/Y probes BM Transplant: ☐ Auto ☐ Allo If Allo- Donor: ☐ Male ☐ Female WBC: _____			
ONCOLOGY FISH PROBE(S) – please select panel or individual probes			
Hematologic panels / probes ☐ AML panel ☐ RUNX1-RUNX1T1 [t(8;21)] ☐ BCR-ABL1 [t(9;22)] ☐ PML-RARA [t(15;17)] ☐ CBFB [inv(16)/t(16;16)] ☐ MLL (KMT2A) (11q23) ☐ EVI1 (MECOM) [t(3;3)/ inv 3q26.2] ☐ TP53 (17p13.1) deletion ☐ Secondary AML / High-Risk MDS ☐ 5q31 (EGR1) deletion / -5 ☐ 7q31 deletion / -7 ☐ MLL (KMT2A) [11q23] ☐ TP53 (17p13.1) deletion ☐ MDS panel ☐ 5q31 (EGR1) deletion / -5 ☐ 7q31 deletion / -7 ☐ Trisomy 8 ☐ 20q12 deletion ☐ Optional: TP53 (17p13.1) deletion ☐ MPN panel ☐ 5q31 (EGR1) deletion / -5 ☐ 7q31 deletion / -7 ☐ Trisomy 8 ☐ 20q12 deletion ☐ BCR-ABL1 [t(9;22)] ☐ Optional (with MF): 13q14 deletion ☐ Eosinophilia panel ☐ FIP1L1/CHIC2/PDGFRα (4q12) ☐ PDGFRβ (5q32) ☐ FGFR1 (8p11.2) ☐ ETV6 (12p13) ☐ CML panel ☐ BCR-ABL1 [t(9;22)] ☐ Optional Accelerated Phase panel ☐ EVI1 (MECOM) [t(3;3)/ inv 3q26.2] ☐ Trisomy 8 ☐ RARA gain of 17q / iso17q ☐ Trisomy 19		Hematologic panels / probes (continued) ☐ B-ALL (Adult) ☐ MYC (8q24) ☐ BCR-ABL1 [t(9;22)] ☐ MLL (KMT2A) [11q23] ☐ IGH (14q32) ☐ CRLF2 (Xp22.33/Yp11.32) ☐ B-ALL (Pediatric / COG) ☐ Trisomy 4 and 10 ☐ BCR-ABL1 [t(9;22)] ☐ MLL (KMT2A) (11q23) ☐ ETV6-RUNX1 [t(12;21)] ☐ TCF3-PBX1 [t(1;19)] ☐ CRLF2 (Xp22.33/Yp11.32) ☐ Reflex B-ALL panel ☐ PDGFRβ (5q32) ☐ ABL1 (9q34) ☐ IGH (14q32) ☐ ABL2 (1q25) ☐ T-ALL panel ☐ TCR Alpha/Delta (14q11.2) ☐ MLL (KMT2A) (11q23) ☐ Myeloma panel (enriched plasma cells) ☐ CKS1B (1q21 gain)/CDKN2C (1p32 loss) ☐ 5q31 (EGR1) deletion / -5 ☐ 13q14 deletion / -13 ☐ IGH (14q32) ☐ TP53 (17p13.1) deletion ☐ Reflex Myeloma panel ☐ FGFR3-IGH [t(4;14)] ☐ CCND1-IGH [t(11;14)] ☐ IGH-MAF [t(14;16)] ☐ IGH-MAFB [t(14;20)] ☐ CLL panel ☐ ATM (11q22.3) deletion ☐ Trisomy 12 ☐ 13q14 deletion / -13 ☐ TP53 (17p13.1) deletion ☐ MYB (6q23) deletion ☐ CCND1-IGH [t(11;14)]	
		Lymphoma panels / probes ☐ NHL (DLBCL) panel ☐ MYC (8q24), MYC-IGH [t(8;14)] ☐ BCL2-IGH [t(14;18)] ☐ BCL6 (3q27) ☐ LBCL IRF4/ DUSP22 (6p25.3) ☐ Anaplastic LBCL ALK (2p23) ☐ Follicular BCL2-IGH [t(14;18)] ☐ Mantle Cell CCND1-IGH [t(11;14)] ☐ Burkitt MYC (8q24), MYC-IGH [t(8;14)] ☐ MALT MALT1 (18q21.3), API2 (BIRC3)-MATL1 [t(11;18)] ☐ Splenic Marginal Zone ☐ Trisomy 3 (BCL6) ☐ Deletion 7q ☐ Nodal Marginal Zone ☐ Trisomy 3 (BCL6) ☐ Trisomy 18 (BCL2) ☐ MYB (6q23) deletion ☐ Immunoglobulin Rearrangement panel ☐ IGH (14q32) ☐ IGK (2p11.2) ☐ IGL (22q11.1) ☐ T-Cell ☐ TCR Alpha/Delta (14q11.2) ☐ Isochromosome 7q	
		Solid Tumor probes ☐ 1p36/19q13 co-deletion ☐ ALK 2p23 (Lung, Thyroid Carcinoma, Inflammatory Myofibroblastic Tumor) ☐ CDKN2A (p16) 9p21.3 (Various Tumors) ☐ CCND1 11q13 (RCC, Lymphoma) ☐ COL1A1 17q21.33 (Dermatofibrosarcoma Protuberans/Giant Cell Fibroblastoma) ☐ DDIT3 (CHOP) 12q13.3 (Myxoid/Round Cell Liposarcoma) ☐ EGFR amp 7p11.2 (Various Tumors) ☐ ETV6 12p13.2 (Various Tumors) ☐ EWSR1 22q12.2 (Ewing Sarcoma, PNET, Salivary Gland Carcinoma, Various Tumors) ☐ FGFR1 8p11.2 (Squamous Cell Breast Carcinoma) ☐ FOXO1 (FKHR) 13q14.11 (Alveolar Rhabdomyosarcoma) ☐ FUS 16p11.2 (Myxoid/Round Cell Liposarcoma, Angiomatoid Fibrous Histiocytoma) ☐ Iso12p (Germ Cell Tumor) ☐ MDM2 amp 12q15 (Well-Differentiated Liposarcoma, Osteosarcoma) ☐ MET amp 7q31.2 (Various Tumors) ☐ MYC amp 8q24.21 (Various Tumors) ☐ MYCN amp 2p24.3 (Neuroblastoma) ☐ PTEN 10q23.31 (Various Tumors) ☐ RET 10q11.23 (Various Tumors) ☐ ROS1 6q22.1 (Various Tumors) ☐ SS18 (SYT) 18q11.2 (Synovial Sarcoma, Salivary Gland Adenocarcinoma) ☐ TFE3 Xp11.23 (RCC, Alveolar Soft Part Sarcoma) ☐ USP6 17p13.2 (Aneurysmal Bone Cyst, Nodular Fasciitis) ☐ VHL 3p25.3 (RCC)	
		Solid Tumor panels ☐ ERBB2 (HER2) amp 17q12 * Ischemic time _____ mins * Fixation Time _____ hrs ☐ Lung Cancer panel ☐ ALK 2p23 ☐ MET amp 7q31.2 ☐ ROS1 6q22.1 ☐ RET 10q11.2 ☐ Glioma panel ☐ 1p/19q co-deletion ☐ CDKN2A 9p21.3 ☐ EGFR amp 7p11.2 ☐ PTEN 10q23.31 ☐ Uveal Melanoma panel ☐ Monosomy 3 ☐ Gain of 6pter	
		Urine FISH / Bladder Cancer ☐ Aneuploidy 3,7,17 and deletion 9p21	
TRANSPORT TO THE LABORATORY ASAP; STORE AT ROOM TEMPERATURE. Peripheral Blood: 4-8 mL (neonates 2 mL			